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Abstract
Plasmodium falciparum in western Cambodia has developed resistance to artemisinin and its partner drugs, causing frequent
treatment failure. Understanding this evolution can inform the deployment of new therapies. We investigated the genetic
architecture of 78 falciparum isolates using whole-genome sequencing, correlating results to in vivo and ex vivo drug resistance
and exploring the relationship between population structure, demographic history, and partner drug resistance. Principle com-
ponent analysis, network analysis and demographic inference identified a diverse central population with three clusters of clonally
expanding parasite populations, each associated with specific K13 artemisinin resistance alleles and partner drug resistance
profiles which were consistent with the sequential deployment of artemisinin combination therapies in the region. One cluster
displayed ex vivo piperaquine resistance and mefloquine sensitivity with a high rate of in vivo failure of dihydroartemisinin-
piperaquine. Another cluster displayed ex vivo mefloquine resistance and piperaquine sensitivity with high in vivo efficacy of
dihydroartemisinin-piperaquine. The final cluster was clonal and displayed intermediate sensitivity to both drugs. Variations in
recently described piperaquine resistance markers did not explain the difference in mean IC90 or clinical failures between the high
and intermediate piperaquine resistance groups, suggesting additional loci may be involved in resistance. The results highlight an
important role for partner drug resistance in shaping the P. falciparum genetic landscape in Southeast Asia and suggest that
further work is needed to evaluate for other mutations that drive piperaquine resistance.
Key words: plasmodium, partner drug, piperaquine, mefloquine, drug resistance, ACT, malaria, population genetics,
pfmdr1, kelch, ex vivo susceptibility.
Introduction
Mortality due to malaria nearly halved over the last 15 years,
due in part to the adoption of artemisinin-based combination
therapies (ACT). ACT is comprised of a potent, short-acting
artemisinin derivative paired with a longer-acting partner
drug. This allows ACT to be administered over just 3 days,
but leads to a long terminal phase of partner-drug monother-
apy (Fairhurst 2015; Taylor and Juliano 2014). Thus, as arte-
misinin resistance increases and parasites take longer to clear,
the probability of developing resistance to the partner drug
 The Author 2017. Published by Oxford University Press on behalf of the Society for Molecular Biology and Evolution.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Genome Biol. Evol. 9(6):1673–1686. doi:10.1093/gbe/evx126 Advance Access publication July 11, 2017 1673
GBE
also increases, leading to ACT failure. Resistance to ACT rep-
resents a major threat to malaria-control efforts worldwide
and has now been reported in five countries in Southeast Asia
(Ashley et al. 2014). Efforts are underway to stem the rising
tide of resistance in the region, and new antimalarial regimens
are desperately needed.
Intensive research into the mechanisms of resistance to
artemisinin, mefloquine (MQ) and piperaquine (PPQ) have
revealed molecular markers of resistance to the last two
ACTs used in the region, artesunate-mefloquine (AS-MQ)
and dihydroartemisinin-piperaquine (DHA-PPQ) (Leang et al.
2015; Spring et al. 2015). Artemisinin resistance is associated
with mutations in kelch (K13) (Ariey et al. 2014; Miotto et al.
2015; Takala-Harrison et al. 2012; MalariaGEN Plasmodium
falciparum Community Project 2016). MQ resistance has for
some time been associated with increases in Plasmodium fal-
ciparum multidrug resistance gene 1 (pfmdr1) copy number.
More recently, two mutations have been associated with re-
sistance to PPQ, a copy-number variation encompassing plas-
mepsin II and III and a Glu415Gly substitution within an
exonuclease (Amato et al. 2017; Witkowski et al. 2017).
However, it is unknown whether these mutations explain all
ACT failures in the region (Mukherjee et al. 2017).
The emergence of drug resistance in the region has led to
strong population substructuring, which has been ascribed to
artemisinin resistance (Ariey et al. 2014; Miotto et al. 2015;
Takala-Harrison et al. 2012; MalariaGEN Plasmodium falcipa-
rumCommunity Project 2016). However, previous population
genomics analyses have not explored the potential role of
ACT partner drugs, in conjunction with artemisinin deriva-
tives, in shaping these subpopulations. Increasing PPQ resis-
tance has been accompanied by increasing MQ sensitivity
(Leang et al. 2015; Chaorattanakawee et al. 2015, 2016)
which has led to interest in the use of triple ACT (TACT),
combining an artemisinin derivative with both MQ and PPQ
(Maxmen 2016). TACT is predicated upon the premise that
parasites with resistance to both partner drugs have not yet
developed, and that PPQ and MQ may exert opposing selec-
tion pressures if used simultaneously. Understanding the re-
lationship between subpopulations in regard to partner drug
resistance may provide evidence to support the use of TACT in
the region.
To better understand how resistance to artemisinin and
these two partner drugs (MQ and PPQ) has evolved in
Cambodia, we investigated the genetic architecture of 78 P.
falciparum parasites drawn from three provinces in western
Cambodia between 2011–2014, including 60 from a cohort
with a>50% rate of DHA-PPQ failure (Chaorattanakawee
et al. 2015; Spring et al. 2015). Whole-genome sequencing
revealed stark genetic structuring among the samples. We
integrated the genetic findings with ex vivo PPQ and MQ
resistance profiles as well as in vivo responses to DHA-PPQ
therapy, finding resistance to ACT partner drug correlated
with different parasite subpopulations. This differentiation
of piperaquine versus mefloquine-resistant parasite subpopu-
lations supports a triple ACT strategy. A single parasite sub-
population in particular was associated with high PPQ IC90s
and DHA-PPQ treatment failure. Although recently described
candidate markers for PPQ resistance are predominantly mu-
tant in this highly resistant subpopulation, they were also pre-
sent in a subpopulation with intermediate piperaquine
sensitivity and a lower rate of DHA-PPQ failure. Thus, further
studies to identify other loci involved in PPQ resistance are
warranted. Further molecular surveillance and in vitro studies
of these subpopulations could help identify additional PPQ
resistance loci and help to determine the likelihood that P.
falciparum resistant to TACT regimens currently being
deployed will emerge in the near future.
Materials and Methods
Study Population
We studied parasites collected from 78 adults with uncompli-
cated P. falciparum infection from three provinces of Western
Cambodia: Oddar Meanchey in the North (n¼ 61),
Battambang (n¼ 8) in the West and Kampot in the South
(n¼ 9). These samples were collected between June 2011
and December 2013 and represent a subset of samples se-
quenced for a previous study (Parobek et al. 2016). Sixty of
the samples in Oddar Meanchey came from an in vivo efficacy
study of DHA-PPQ in which 54% of patients developed re-
crudescent parasitemia requiring rescue therapy with AS-MQ
(clinical trial protocol WR1877 [NCT01849640]) (Spring et al.
2015). An additional 18 P. falciparum clinical isolates from
inside and outside of Oddar Meanchey Province were selected
at random from an in vitro surveillance study (protocol
WR1576), for which clinical follow-up data was not collected
(Chaorattanakawee et al. 2015). Both studies were approved
by the Cambodian National Ethics Committee for Health
Research and the Walter Reed Army Institute of Research
Institutional Review Board. The molecular studies described
herein were approved by the University of North Carolina
Institutional Review Board (14-0419). All subjects provided
informed consent.
Drug Susceptibility Testing
Immediate ex vivo drug susceptibilities to PPQ and MQ were
measured using a histidine-rich protein 2 (HRP-2) enzyme-
linked immunosorbent assay (Chaorattanakawee et al.
2015; Rutvisuttinunt et al. 2012; Saunders et al. 2015).
Whole-Genome Sequencing and CNV Determination
Leukodepleted DNA from 91 P. falciparum infections was
used for whole-genome sequencing. The ratio of parasite
DNA to host DNA was determined using a quantitative PCR
assay, and isolates with20% P. falciparum DNA were
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sequenced on the HiSeq2000 Sequencing System (Illumina,
San Diego, CA) (Beshir et al. 2010). Sequence reads were
aligned to the P. falciparum 3D7 (v3) genome using the
bwa mem algorithm. Isolates with 5-fold coverage at60%
of the genome were considered for variant calling, resulting in
calls for 78 isolates. Coverage over coding regions was not
used as a criteria for isolate inclusion, though all included
samples did have robust coverage over coding regions (see
supplementary Results, Supplementary Material online).
Variant calling was performed using the GATK
HaplotypeCaller utility. Further details are described in the
supplementary Methods, Supplementary Material online.
WGS data was used for calling all variation, both SNP and
CNV, as previously described (Parobek et al. 2016). CNVs at
select loci were also evaluated by qPCR: pfmdr1 copy-number
calls were integrated from previously published data
(Chaorattanakawee et al. 2015; Lim et al. 2015; Eastman
et al. 2011), and plasmepsin-II and -III CNs were ascertained
experimentally (see supplementary Methods and table S3,
Supplementary Material online). In both cases, isolates with
with CN1.5 were considered to represent increased copy
number. Quantitative PCR data was used for all analysis.
Assessment of Population Structure and Demography
Whole-genome variant data were used to determine the prin-
cipal components of genetic variation (Jombart and Ahmed
2011; Paradis 2010). Cluster assignments were determined
using a nonparametric k-means approach, and clusters were
assigned a unique “Cambodian Parasite” (CP) identifier. To
create the network tree, variant calls were read into R using
pegas (Paradis 2010) and a neighbor-joining tree was con-
structed using ape (Paradis et al. 2004) and bootstrapped to
100 replicates. The clonality of each population cluster was
rigorously tested by comparing point estimates of linkage dis-
equilibrium decay with bootstrap replicates drawn randomly
from all sequenced isolates and by assessing pairwise total
number of single nucleotide polymorphism (SNP) differences
between each pair of isolates within a subpopulation.
Observed minor allele frequencies were calculated and com-
pared with the frequencies expected from an idealized pop-
ulation, modeled using ms (Hudson 2002). The folded site-
frequency spectrum was used to infer demographic parame-
ters and likelihoods under a number of two-population mod-
els (Gutenkunst et al. 2009). The tested scenarios were no
split (Static, the two clusters are drawn from the same popu-
lation), split with isolation (Iso, the two populations split at
some past time T), and split with migration (IM, the two
populations split at some past time T with subsequent migra-
tion between the split populations). Simulations have found
that the 7000þ variants we report here are an order of mag-
nitude more numerous than needed for robust demographic
inference (Robinson et al. 2014). 100 bootstrapped replicates
were constructed, and each of the above models was fitted to
each of these replicates 100 times. Genewise FST between
subpopulations was calculated and rendered in R (R
CoreTeam, Vienna, Austria) (Pfeifer et al. 2014; Gu et al.
2014). For further details on population-genetic methods,
see the supplementary Materials, Supplementary Material
online.
Statistical Analysis
Median PPQ IC90 and MQ IC50 values were compared be-
tween PCA clusters using the Kruskal–Wallis test. The
Wilcoxon–Mann–Whitney test was used to compare the me-
dian PPQ IC90 values of isolates with and without select can-
didate resistance markers, as well as the median MQ IC50
values of recrudescent versus nonrecrudescent parasites.
Fisher’s exact test was used to compare the frequency of in-
creased pfmdr1 copy number amongst recrudescent parasites
and those that did not recrudesce and, in a post-hoc analysis,
the frequency of increased pfmdr1 copy number, the exonu-
clease E415G mutation, and increased plasmepsin-II and -III
copy number between PCA groups, with Bonferonni cor-
rected thresholds for statistical significance to account for
multiple comparisons. We analyzed 42-day cumulative risk
of recrudescent malaria via survival-analysis with Kaplan–
Meier curves and compared the risk by cluster and by PPQ
resistance markers using Cox proportional hazards models.
Statistical analyses were completed using SAS 9.4 (SAS
Institute, Cary, NC) and figures were generated using R.
Results
Whole-Genome Sequencing, Network Analysis and
Demographic Inference Show Subpopulations Undergoing
Epidemic Expansion
Whole-genome sequencing of 78 P. falciparum clinical iso-
lates produced, on average, >10-fold coverage in 94.7% of
coding regions and >5-fold coverage in 99.5% of coding
regions. Stringent variant calling within these samples identi-
fied 7,228 high-quality, genome-wide SNPs. The allele-
frequency spectrum for the population showed two notable
features: 1) an overrepresentation of rare alleles, and 2) an
overrepresentation of intermediate-frequency alleles relative
to the neutral expectation (supplementary fig. S1,
Supplementary Material online). An excess of rare alleles
can be observed in expanding populations, as mutations
that have occurred since the onset of expansion have not
had sufficient time to spread through the population
(Maruyama and Fuerst 1984). An excess of intermediate fre-
quency alleles suggests the existence of two or more genet-
ically unique subpopulations (Hurst 2009; Nielsen and Rasmus
2005; Kreitman 2000). To explore the latter finding, we per-
formed principal components analysis (PCA) of genetic varia-
tion to summarize the underlying population structure among
these samples. The first two principal components (PCs)
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explained 52% of the variance and revealed four distinct pop-
ulation subclusters (fig. 1A and B). Components beyond the
third PC were less informative (supplementary fig. S2A–D,
Supplementary Material online). K-means clustering using
the top three principal components assigned individuals to
four genetically distinct clusters, which we named CP1
(n¼ 17), CP2 (n¼ 18), CP3 (n¼ 20), and CP4 (n¼ 23) (sup-
plementary fig. S3, Supplementary Material online). We
found that genetic dissimilarity was not explained by geogra-
phy, as all clusters except for one (CP4) contained parasites
from more than one geographic location (supplementary fig.
S4, Supplementary Material online). Therefore, this popula-
tion substructuring is driven by a factor that supersedes ge-
netic drift.
Network analysis shows that CP2 has, on average, longer
terminal branch lengths and deeper internal nodes, findings
that suggest an older most recent common ancestor for CP2
members than for CP1, CP3, or CP4 members (fig. 2). In
addition, the outlying subpopulations appear more clonal by
network analysis. Therefore, we assessed the population
FIG. 1.—Principal components analysis demonstrates distinct clusters with non-overlapping resistance profiles. In the upper panels, nodes are scaled
according to piperaquine IC90 and mefloquine IC50 values, with the largest nodes representing IC90 values of 1,000 nM or greater for piperaquine. Panel A
displays PPQ IC90 values, and panel B displays MQ IC50 values. Blue samples comprise cluster CP1, red CP2, green CP3, and yellow CP4. In the lower panels,
IC90 values by cluster are depicted for PPQ in panel C and IC50 values for MQ in panel D. Boxplots display the median (horizontal line), interquartile range
(box), and the lowest and highest data point within 1.5 times the IQR (whiskers) of the values [values outside this range are plotted as individual points]. One
PPQ IC90 outliers were clipped from cluster CP4 in panel C and labeled with an asterisk (*). There was a statistically significant difference among the four
groups for PPQ (Kruskal–Wallis P¼0.0005) IC90 values and for MQ (P¼0.004) IC50 values. Noise has been added to the PCA to reduce overplotting.
Samples are plotted only if information is available for them, thus some positions may appear different. Abbreviations: PC, principal component; IC50, half-
maximal inhibitory concentrations.
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diversity and linkage disequilibrium (LD) within each subpop-
ulation. Analysis of LD in each of the four populations confirm
a higher degree of linkage disequilibrium within the CP1 and
CP4 subpopulations versus CP2 (supplementary fig. S5,
Supplementary Material online). The extreme clonality of
CP3 prevented calculation of r2 for this subpopulation. The
number of pairwise SNP differences within each cluster also
revealed that the ACT-resistant subgroups—and particularly
CP3 and CP4—are clonal or nearly clonal, with greatly
reduced within-group diversity compared with the
FIG. 2.—Neighbor-joining network tree of P. falciparum isolates. A rooted and bootstrapped (100 replicates) neighbor-joining network tree of the
Cambodian P. falciparum isolates is shown. The specific isolates are colored by CP group: CP1 blue, CP2 red, CP3 green, and CP4 yellow. The tree is rooted
with 3D7, an isolate of African origin.
Genetic Architecture of ACT Partner Drug Resistance GBE
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ancestral-like CP2 population (supplementary fig. S6,
Supplementary Material online). Strikingly, the greatest num-
ber of SNP differences observed in pairwise comparisons
among CP3 isolates was four. Lastly, we compared the ge-
netic diversity in our clusters to the recently reported genetic
architecture of artemisinin-resistant P. falciparum (Miotto
et al. 2015, 2013). Based on 7,214 SNPs common to both
data sets, we determined that our populations fall within the
scope of diversity previously described (supplementary fig.
S7A–C, Supplementary Material online), and contain less ge-
netic diversity than their overlayed population (supplementary
table S1, Supplementary Material online). These data suggest
that CP1, CP3, and CP4 may represent epidemic expansion of
parasite subpopulations, potentially from CP2 and potentially
due to drug resistance (Daniels et al. 2013).
To confirm this finding, and to determine the timing and
direction of the subpopulation splits, we fit various two-
population demographic scenarios to the allele frequency
spectra of CP subgroup pairs (see supplementary Materials,
Supplementary Material online). To test a broad range of
demographic models and parameter space, we used a
diffusion-based inference approach based on the
multi-population allele frequency spectrum (supplementary
fig. S8, Supplementary Material online), rather than a
coalescent-theory based Monte Carlo approach
(Gutenkunst et al. 2009). This approach has been used for
efficient inference of recent demographic events in popula-
tions within nonmodel species including Plasmodium (McCoy
et al. 2014; Chang et al. 2012). These two-population sce-
narios assume an ancestral coalescent state and explicitly test
which subpopulation is descended from a founder event.
Fitting two-population models to the CP2 versus CP1/CP3/
CP4 cluster pairs demonstrated that CP1 (n¼ 17) and CP4
(n¼ 23) likely derived from a CP2 ancestral-like population
(n¼ 18), and that CP2–CP1 split occurred prior to CP2–CP4
split (supplementary table S2, Supplementary Material online).
However, in both cases, the best fit models suggest split with
back migration resulting in potential genetic mixing of the
populations.
Distinct Subpopulations Correlate with Ex Vivo Partner-
Drug Resistance
Our isolates follow a pattern of alternate resistance profiles, in
which samples with high PPQ IC50 values exhibit low MQ IC50
values, and vice versa (fig. 3). We found that these differing
FIG. 3.—Piperaquine and mefloquine IC50 values associated with parasite subpopulations in Cambodia. Subjects who had both piperaquine and MQ
IC50 values are displayed. Those who later had an episode of recrudescence are displayed using solid orange triangles, whereas those who did not have an
episode of recrudescence or did not have follow-up data available are displayed using solid navy circles. Two isolates that had recrudescence with very high
piperaquine IC50 values (307.0 and 397.1nM) are represented with hollow symbols.
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PPQ- and MQ-resistance profiles correlate with the genetic
substructure found by whole genome sequencing. Mean ex
vivo resistance to PPQ was highest in one cluster, CP4,
whereas mean ex vivo resistance to MQ was highest in an-
other cluster, CP1. This is depicted in figure 1A and B, where
points in the PCA represent individual clinical isolates and are
sized according to their respective PPQ IC90 and MQ IC50
values. PPQ IC90 values were analyzed because they are
more predictive of resistance than IC50 values for PPQ
(Chaorattanakawee et al. 2016). Comparative analysis of me-
dian PPQ IC90 and MQ IC50 values by cluster shows different
drug-resistance profiles among the four groups (fig. 1C and
D). The median PPQ IC90 values were: 62.4 nM (interquartile
range 45.5–70.7) for CP1, 201.4 nM (97.8–360.4) for CP2,
288.6 nM (85.4–678.4) for CP3, and 667.4 nM (136.3–
2523.7) for CP4 (Kruskal–Wallis P¼ 0.0005). The median
MQ IC50 values were: 143.0 nM (IQR 53.9–173.9) for CP1,
9.1 nM (1.2–63.7) for CP2, 47.8 nM (23.0–62.7) for CP3, and
33.1 nM (4.8–42.7) for CP4 (Kruskal–Wallis P¼ 0.004).
A Single Parasite Subpopulation Is Associated with DHA-
PPQ Treatment Failures
The in vivo phenotypes for parasite clearance half-life and
treatment efficacy were available for 60 of the isolates.
Patients who failed DHA-PPQ therapy were disproportionately
infected with parasites from the PPQ-resistant CP4 group.
Among the 58 subjects followed for 7 weeks after DHA-
PPQ treatment, there were no recrudescence events in CP1
(n¼ 11, 0%), two in CP2 (n¼ 8, 25%), four in CP3 (n¼ 16,
25%), and 18 in CP4 (n¼ 23, 78%). Survival analysis dem-
onstrated that subjects infected with parasites from cluster
CP4 were more likely to suffer recrudescence after treatment
with DHA-PPQ than those from other clusters (hazard ratio
7.9, 95% CI 3.0–20, P< 0.001) (fig. 4). Though determina-
tion of recrudescence by standard WHO genotyping
procedures is potentially complicated in populations that are
highly clonal, the fact that initial and recurrent parasitemias in
these patients shared a genotype would suggest a reinfection
by the same clonal line if it was not a true recrudescence. CP4
parasites also harbored the C580Y mutation and seemed to
display the longest parasite clearance half-lives, consistent
with artemisinin resistance. However, C580Y enrichment
and parasite clearance half-lives were not significantly differ-
ent in the CP3 group (supplementary fig. S9, Supplementary
Material online), despite lower rates of DHA-PPQ failure.
Candidate Partner Drug Resistance Markers Explain Ex Vivo
MQ Resistance but Do Not Differentiate Intermediate and
High Ex Vivo PPQ Resistance
We used the sequence data to investigate single nucleotide
polymorphism markers of artemisinin, PPQ and MQ resistance
in the isolates. In addition, we evaluated copy number varia-
tion (CNV) of pfmdr1 and plasmepsin-II and -III using both
whole-genome sequence data and real-time PCR. Relative
to real-time PCR, sequence data had a sensitivity and specific-
ity for CNV detection of 82.4% and 100% for pfmdr1 and
93.3% and 92.5% for plasmepsin-II and -III, respectively.
Given inconsistent genome coverage characteristic of P. fal-
ciparum short-read sequencing projects, we chose to use real-
time PCR data rather than whole genome sequencing data
for CNV analyses.
Investigation of molecular markers of partner drug resis-
tance showed an expected increase in pfmdr1 CNV in the
MQ-resistant CP1 parasites (fig. 5) (Chaorattanakawee et al.
2015). Newly described candidate markers of PPQ resistance
(Witkowski et al. 2017; Amato et al. 2017), including the
plasmepsin-II and -III copy number variant and the exonucle-
ase E415G mutation, were associated with treatment failure;
subjects with mutant alleles at both markers were more likely
to suffer recrudescence than those who lacked either or both
markers (hazard ratio 16.8, 95% CI 2.2–127, P¼ 0.006, fig.
6). There was a range of one to three plasmepsin-II and -III
copies detected in our isolates. However, these alleles, which
discriminated between the populations with lower PPQ IC90
values (CP1 and CP2) and those with higher PPQ IC90 values
(CP3 and CP4), did not discriminate between the intermediate
PPQ resistance (CP3) and higher PPQ resistance (CP4) popu-
lations (fig. 5). This suggests that other genetic loci may drive
this difference. Lastly, all parasites in the study were wild type
at Plasmodium falciparum chloroquine resistance transporter
(pfcrt) loci, at residues 97, 343, and 353, previously described
by Duru et al. (2015).
Clinical and Molecular Data Support Alternating
Sensitivities to Partner Drugs
Available clinical and molecular data support the hypothesis
that DHA-PPQ treatment failures in our cohort are MQ-
sensitive. In the original clinical study, 46 subjects who failed
FIG. 4.—Recrudescence after DHA-PPQ by cluster. Kaplan–Meier
curves demonstrate the risk of recrudescence by cluster (Wald P<0.001
for CP4 compared with other clusters). Red crosses represent patients
censored for withdrawal or development of new infection.
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DHA-PPQ treatment and developed recurrent malaria were
treated with AS-MQ, per national guidelines (Spring et al.
2015; Chaorattanakawee et al. 2015). After this rescue treat-
ment, only one subject (2.2%) had a second recurrent malaria
infection during limited follow-up (median 15 days, range 4–
33 days). In that subject, PCR genotyping demonstrated that
the initial recurrence was a new infection, not a recrudes-
cence due to DHA-PPQ failure. Thus, no early treatment
failures occurred in 46 patients when AS-MQ was given for
DHA-PPQ failure, though follow-up times were insufficient to
rule out late treatment failures. Additionally, data from the
original study showed only one of 35 (2.9%) recrudescent
isolates among DHA-PPQ treatment failures had increased
pfmdr1 CN (associated with MQ resistance), whereas 10 of
59 (16.9%) isolates from patients who successfully cleared
parasites after DHA-PPQ treatment had increased copy num-
ber (P¼ 0.05) (Spring et al. 2015; Chaorattanakawee et al.
2015). Accordingly, lower MQ IC50 values were measured in
DHA-PPQ treatment failures (median 32.3 nM, interquartile
range 9.3–51.6) compared with cures (48.0 nM, 21.0–108.1)
(P¼ 0.03).
Extended K13 and Partner Drug Resistance Marker
Haplotypes Are Shared among Parasite Subpopulations
In addition to differing partner-drug resistance profiles, our
subpopulations were also correlated with specific K13
(PF3D7_1343700) genotypes. C580Y, the most common
K13 mutation in Cambodia, was found in all CP3 and CP4
isolates (supplementary fig. S10 and S1, Supplementary
Material online). The second most common K13 mutation,
R539T, occurred exclusively in CP1, but this group also con-
tained C580Y mutations. Lastly, CP2 contained a few differ-
ent K13 mutations, including many isolates with C580Y. This
pattern of subpopulations associated with specific K13 sub-
types is similar to previous reports of “KH” subpopulations in
Cambodia defined by K13 alleles (Miotto et al. 2015), and
suggests that population fracturing may have occurred along
artemisinin resistance subtypes. We investigated SNPs occur-
ring 50 kb upstream and downstream of C580Y. Although
we did find multiple C580Y haplotypes in the overall popula-
tion consistent with the C580Y mutation arising on multiple
genetic backgrounds, a single identical extended C580Y
FIG. 5.—Proportion of isolates bearing partner drug resistance
markers by cluster. The proportion of subjects with increased pfmdr1
copy number (A), increased plasmepsin-II and -III copy number (B) and
the exonuclease E415G mutation (C) are shown. Comparison of CP3
and CP4 did not reveal statistically significant differences in the proportion
of isolates bearing plasmepsin-II and -III copy number or exonuclease
E415G mutation, with P values of 0.06 and 1.0, respectively (Bonferroni
corrected threshold for significance of 0.0083).
FIG. 6.—Recrudescence after DHA-PPQ by PPQ resistance markers.
Kaplan–Meier curves demonstrate the risk of recrudescence by PPQ resis-
tance markers (Wald P¼0.006 for subjects with both a plasmepsin-II and -
III copy number variant and the exonuclease E451G mutation compared
with others). Red crosses represent patients censored for withdrawal or
development of new infection.
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haplotype predominated and was shared across all clusters
(fig. 7A). This suggests that despite their substructuring, para-
sites from all clusters contain C580Y mutations from a single
origin, consistent with recent evidence of a dominant haplo-
type sweeping the region (Imwong et al. 2017). Thus, the
separation of CP3 and CP4 cannot be explained by K13-
associated artemisinin resistance. A similar analysis of ex-
tended haplotypes in CP1, the MQ-resistant population,
revealed a single R539T haplotype (fig. 7B) accompanied by
two C580Y haplotypes that are both shared with the diverse
CP2 population (fig. 7A).
Extended haplotypes surrounding partner drug resistance
genes show different profiles. For the plasmepsin-II and -III
copy number variant, a pattern similar to that at K13 emerges.
All plasmepsin CNVs occur on a single haplotype, which pre-
dominates in CP3 and CP4 and which also occurs in the other
two subpopulations (fig. 7C). Two CP2 isolates bear the plas-
mepsin CNV and are associated this extended haplotype,
though additional CP2 isolates bear the plasmepsin haplotype
without the CNV itself. Conversely, the extended haplotypes
surrounding pfmdr1within CP1 are not shared with any other
subpopulation and are relatively conserved within CP1
whether or not a parasite had a detected duplication (fig. 7D).
Genomic Regions Differentiating CP3 and CP4 May Be
Linked to High DHA-PPQ Clinical Failure Rate in CP4
Though this study was underpowered to detect statistically
significant associations between individual genetic variants
and clinical phenotypes, we nonetheless used population ge-
netic approaches to explore genomic differences between
CP3 and CP4. We chose to compare these two populations
as there was little genetic diversity between CP3 and CP4, but
a large clinical phenotype difference between subpopulations.
Pairwise FST of CP3 versus CP4 revealed large genomic regions
with genes that were either identical or highly divergent (sup-
plementary fig. S12, Supplementary Material online).
Importantly, as suggested by supplementary figures S10
and S11, Supplementary Material online and figure 7, the
genomic regions containing candidate PPQ resistance loci
are identical between the two populations, suggesting other
loci may drive the clinical phenotype difference between these
groups. Pairwise FST calculated between CP4–CP2 and CP3–
CP2 subpopulations showed a less dichotomous pattern, with
a more diverse range of values (supplementary fig. S12,
Supplementary Material online). In addition, differences be-
tween CP1 and CP2 showed less striking divergence between
the groups (supplementary fig. S12, Supplementary Material
online) as suggested in our network analysis (fig. 2).
To explore which variants in the CP3–CP4 divergent
regions contribute to the failure phenotype, we investigated
the contribution of each SNP (determined by loading values)
to principal component two (PC2), as PC2 explains nearly all
the genetic difference between these two subgroups
(supplementary fig. S13, Supplementary Material online).
This can be seen by comparing the PC1–PC2 PCA (fig. 1A
and B; supplementary fig. S2B, Supplementary Material on-
line), where the populations split along PC2, to the PC1–PC3
PCA (supplementary fig. S2C, Supplementary Material on-
line), where the populations collapse on each other. We
found that the majority of variation between CP3 and CP4
is driven by 1,006 variants, including 330 missense or non-
sense mutations exclusive to CP4, which are located in 206
genes (supplementary Appendix S2 and S3, Supplementary
Material online). After Bonferroni correction, gene-ontology
analysis showed no enrichment of specific biological pro-
cesses among these genes.
Discussion
The P. falciparum population in Southeast Asia has been the
focus of intense malaria control and elimination efforts over
the past two decades. This has shaped a complex population
structure marked by fractured subpopulations. Most work
describing this genetic architecture has focused on artemisinin
resistance as a selective force, showing that subpopulations
associate with specific K13 mutations (Miotto et al. 2015,
2013). However, until recently, little attention has been given
to the role of partner drug resistance in shaping these sub-
populations. Rising ACT resistance in Southeast Asia leading
to the failure of the last two ACT regimens in Cambodia
makes it critical to understand how partner drugs contribute
to changes in the parasite population. Here, we show that the
P. falciparum population substructure in Cambodia correlates
with partner-drug resistance and represents epidemic expan-
sion of nearly clonal parasite clades. We also show that cur-
rent candidate markers for PPQ resistance do not fully explain
resistance and further studies of one subpopulation, CP4, will
likely shed light on additional loci involved in clinical
resistance.
At our study site in northwestern Cambodia, the first
where high-grade DHA-PPQ resistance was reported, these
subpopulations correlate with different ex vivo and in vivo
patterns of antimalarial resistance. The most concerning find-
ing was that roughly four-fifths of all of the parasites in CP4
subpopulation recrudesced after DHA-PPQ therapy. This
group also had the highest PPQ IC90 values. Surprisingly, para-
sites within this group carried mutations in the newly de-
scribed PPQ resistance markers (Witkowski et al. 2017;
Amato et al. 2017) at a similar frequency as CP3, a group
with lower PPQ IC90 values and only 25% treatment failure
after DHA-PPQ (equivalent to CP2, which had even fewer
resistant parasites by these molecular markers). Differences
between CP3 and CP4 for other antimalarial IC50 values
were not significant other than for quinine (supplementary
fig. S14, Supplementary Material online). FST comparisons of
SNPs between CP3 and CP4 populations showed large geno-
mic regions of near perfect homology contrasting with
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FIG. 7.—Extended haplotypes surrounding artemisinin, piperaquine, and mefloquine drug resistance loci. The extended haplotypes of all SNPs extending
50kb upstream and downstream around K13 in C580Y bearing parasites (A), around K13 in R539T bearing parasites (B), around plasmepsin-II and -III (C) and
around pfmdr1 (D) are shown. In Panel A, one haplotype is shared among all four subpopulations. A second haplotype is shared between CP1 and CP2. In
Panel B, all K13 R539T mutations occurred within CP1 on a single haplotype. In Panel C, one dominant haplotype from CP3 and CP4 is shared among all four
Parobek et al. GBE
1682 Genome Biol. Evol. 1673–1686 doi:10.1093/gbe/evx126 Advance Access publication July 11, 2017
regions of high divergence (supplementary fig. S12,
Supplementary Material online). These highly divergent geno-
mic regions suggest—but cannot pinpoint—genetic drivers
that may confer increased fitness to CP4 parasites in the
face of DHA-PPQ therapy (supplementary Appendices S2
and S3, Supplementary Material online). Though we saw no
enrichment for biological processes among the genes with
mutations unique to CP4 parasites, there are nonetheless in-
triguing polymorphisms exclusive to this highly resistant line-
age. For example, parasites of the CP4 group bore three
missense polymorphisms in PF3D7_0419900, a phosphatidy-
linositol 4-kinase, which has been investigated as a potential
drug target for P. falciparum (Ghidelli-Disse et al. 2014;
McNamara et al. 2013) and been associated with drug resis-
tance in Asia (Cerqueira et al. 2017). In addition, among the
SNPs that differentiate CP3 and CP4 (supplementary S2,
Supplementary Material online), we identified SNPs in prox-
imity, but not identical to other SNPs identified in multiple
GWAS studies of PPQ resistance (MAL8:280180,
MAL12:1787279, MAL12:1959796, MAL14:2385550,
MAL14:2395752, and MAL14:2411942) (Wang et al. 2016;
Amato et al. 2017). Additional studies involving larger num-
bers of isolates with elevated PPQ IC90 values are needed to
further understand genetic determinants of the phenotypic
differences between CP3 and CP4 parasites and will help us
understand how these subpopulations continue to evolve.
Though the genetic determinants of DHA-PPQ failure are
not fully elucidated, understanding how these resistant sub-
populations arose is of key interest. We hypothesized that the
populations CP1, CP3, and CP4 were derived from the cen-
trally positioned CP2 population. Past work has posited the
opposite hypothesis—that the KHA population (which shares
significant overlap with CP2) is an admixture of other popu-
lations circulating in Cambodia (Miotto et al. 2013). Because
these contrasting hypotheses have never been tested, we
used modeling to elucidate the demographic history of these
subpopulations. The two-population demographic compari-
sons presented here suggest that CP2 is an ancestral-like pop-
ulation from which the other populations arose. Consistent
with this, recently derived CP4 (and likely CP3) subpopulations
have undergone rapid expansion despite malaria control
efforts. As evidence, the network tree (fig. 2), diversity (sup-
plementary fig. S6, Supplementary Material online), and LD
(supplementary fig. S5, Supplementary Material online) anal-
yses all suggest that CP1, CP3, and CP4 have lower diversity
than CP2, with varying degrees of clonality. In addition, our
isolates, which were collected relatively recently, show less
genetic diversity than the overlaying subpopulations described
by Miotto et al. (supplementary fig. S7, Supplementary
Material online), suggesting a recent acceleration of subpop-
ulation growth.
Beyond the demographic models, extended haplotypes
surrounding drug resistance genes can also provide insights
to the origins of mutations. Similar to previous work, our
subpopulations associate with specific K13 mutations, with
CP3 and CP4 isolates exclusively C580Y, CP1 primarily
R539T, and the putative ancestral-like population CP2 a mix
of C580Y, other infrequent kelch mutations, and wild-type
isolates (supplementary S1, Supplementary Material online).
In order to better understand the origins of the C580Y and
R539T mutations, we evaluated the extended SNP haplotypes
surrounding K13 (fig. 7A). Isolates with the R539T mutation
exhibited a single haplotype within a solitary subpopulation,
suggesting a single origin of the mutation amongst these
isolates. For C580Y, a single extended haplotype was con-
tained in CP3 and CP4, as well as being present in CP2.
Although K13 mutations historically have arisen through mul-
tiple origins, consistent with “soft selective sweeps” of drug
resistance, the more contemporary nature of these samples
suggests a dominant haplotype is now spreading through in a
“hard selective sweep.” This is consistent with other findings
recently reported in Cambodia (Imwong et al. 2017) and with
the split with migration results from our demographic models.
The pattern is similar for extended haplotypes surrounding
plasmepsin-II and -III copy number variants. All plasmepsin
CNVs occur on a single dominant haplotype, which predom-
inates in CP3 and CP4 and which also occurs in the other two
subpopulations (fig. 7C). Two CP2 isolates bear the plasmep-
sin-II and -III CNV and its associated haplotype, though addi-
tional CP2 isolates bear the plasmepsin-II and -III haplotype
without the CNV itself. Thus, it is possible that the plasmep-
sin-IIand -IIICNVaroseonce inaCP2 isolateandwasassociated
with a subsequent differentiation and expansion of CP3 and
CP4 isolates.Consistentwith this, thepredictedbreakpoints for
the duplication in our isolates were highly conserved [Chr14:
289558 (634) to 298819 (616)] and align to a similar position
to thosepreviously reported (Amatoet al. 2017). Irrespectiveof
the demographic history of these loci, the fact that K13 muta-
tions, the exonuclease E415G, and the plasmepsin-II and -III
CNV exist at similar frequencies in CP3 and CP4 groups and
FIG. 7. Continued
subpopulations. Parasites with an elevated plasmepsin-II and -III copy number are marked with an orange bar within their subpopulation. Parasites with no
evident plasmepsin-II and -III duplication are marked with a purple bar within their subpopulation. In Panel D, a single extended haplotype dominates in CP1
parasites, irrespective if there is pfmdr1 duplication or not, though a highly similar haplotype is found in some nonduplicated CP4 parasites. Parasites with an
elevated pfmdr1 copy number are marked with an orange bar within their subpopulation. Parasites with no evident pfmdr1 duplication are marked with a
purple bar within their subpopulation. SNPs are numbered relative to the center of the gene and dark blue boxes represent nonreferent alleles. The gene is
marked by the red shaded box.
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at different frequencies in CP2 and CP3 groups—yet CP2 and
CP3 groups have similar clinical failure rates while CP3 and CP4
groups have dramatically different clinical failures rates—
suggests that these two locidonot fullyexplainDHA-PPQclinical
failure. Additional loci remain to be found.
The MQ-resistant parasites from CP1 exhibited rela-
tively conserved extended haplotypes around pfmdr1
(fig. 7D), with a dominant haplotype and two additional
highly related haplotypes. The dominant extended pfmdr1
haplotype exists in parasites with and without a duplica-
tion in pfmdr1 within this group. This dominant extended
haplotype associated with ex vivo MQ resistance does not
occur within other subpopulations. However, CP4 con-
tains a highly similar haplotype (different at a single posi-
tion). Similar to Nair et al. (2007), we saw multiple other
genetic backgrounds surrounding pfmdr1 duplications
among all four subgroups. The high prevalence of a single
haplotype within the group exhibiting ex vivo MQ resis-
tance is consistent with an artemisinin-resistant mutation
(e.g., K13 R539T) arising on one of the pfmdr1 back-
grounds and sweeping to a high frequency between the
survey done by Nair and our study.
As many have remarked, ACT in its current form may no
longer be a viable strategy in Southeast Asia (Shanks et al.
2015; Spring et al. 2015; Saunders and Lon 2016). Current
trials of TACT regimens, which incorporate both PPQ and MQ
as partner drugs (Maxmen 2016), are underway. These are
predicated on the premise that parasites with resistance to
both partner drugs have not yet developed and that the two
drugs exert opposing selective pressure. Theoretically, oppos-
ing selective pressure between these drugs may occur. MQ
resistance has been shown to sensitize parasites to chloro-
quine in vitro, consistent with historical observations of a re-
ciprocal relationship between chloroquine and MQ resistance
(Veiga et al. 2014; Barnes et al. 1992; van Es et al. 1994). PPQ
and amodiaquine are 4-aminoquinolines that are related to
chloroquine. It follows that PPQ and MQ may exert opposing
selective pressures based on PPQ’s similarity to chloroquine.
Opposing selective pressure is well described for other anti-
malarials but has yet to be documented for MQ and PPQ
(Venkatesan et al. 2014; Conrad et al. 2014). Our findings
provide some support for TACT by showing that resistance to
PPQ and MQ tend to exist on distinct genetic backgrounds.
However, this does not preclude the possibility that a single
parasite could harbor resistance to both drugs. Indeed, one
clinical isolate (from CP3) demonstrated moderate tolerance
to both PPQ (IC90 1060.1 nM) and MQ (IC50 102.63 nM). This
sample contained the C580Y K13 mutation, the exonuclease
E415G mutation, and the plasmepsin-II and -III CNV, but
lacked a duplication in pfmdr1. Additionally, the presence of
increased pfmdr1 copy number in several parasites in the CP4
group suggests the possibility of growing MQ resistance. The
importance of these findings to public health is unclear, but
they could be a harbinger of TACT-resistant P. falciparum.
In conclusion, we identified a strong relationship between
DHA-PPQ treatment failure and a specific parasite genetic
background among Cambodian P. falciparum parasites and
determined that parasites of different genetic backgrounds
carry different partner drug resistance profiles. This suggests
that the substructuring of parasite populations was likely
driven by a combination of artemisinin and partner-drug re-
sistance, rather than artemisinin alone. Our demographic
models and network analysis suggest that these partner-
drug resistant subpopulations split out of a central
ancestral-like population and have been rapidly expanding;
rather than admixture of multiple preexisting subpopulations
into a central population. Importantly, we found that dif-
ferential DHA-PPQ treatment failure rates are not fully
explained by recently described genetic markers of PPQ
resistance. Mutations in these markers failed to differen-
tiate a subpopulation with high PPQ IC90 and high in vivo
failure (CP4) from one with modestly increased PPQ IC90
and a similar in vivo failure rate to the least drug-resistant
population (CP3). This strongly suggests that additional
loci differentiate these two subpopulations may affect
PPQ resistance. Future interventions and studies should
be guided by an understanding of this evolutionary history
and genetic landscape, which can be leveraged to refine
our understanding of PPQ resistance and the spread of
ACT resistance (Fairhurst 2015).
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Supplementary data are available at Genome Biology and
Evolution online.
Authors Contribution
C.M.P., J.B.P., J.T.L., C.L., D.L.S., S.R.M., and J.J.J. designed
the study. C.M.P., J.B.P., L.N., J.T.L., J.J.J., C.A.L., C.L., M.D.S.,
D.L.S., S.C., and P.G. collected the data. C.M.P., J.B.P., N.F.B.,
L.N., S.C., P.G., E.B., C.A.L., C.L., D.L.S., J.T.L., and J.J.J. did
experiments and analyzed the data. C.M.P., J.B.P., N.F.B.,
J.A.B., J.T.L., D.L.S. and J.J.J. interpreted the data and pre-
pared the report. J.T.L., J.J.J., C.L., and D.L.S. oversaw the
project.
Funding
This work was supported by the National Institutes of Health and the
National Institute of Allergy and Infectious Diseases [5T32AI007151 to
JBP, T32GM007092 and F30AI109979 to CMP, R01AI089819 to JJJ,
and K08 AI110651 to JTL]; the Armed Forces Health Surveillance
Center/Global Emerging Infections Surveillance and Response System;
Military Infectious Disease Research Program; and the American Society
of Tropical Medicine and Hygiene/Burroughs Wellcome Fund [fellowships
to JTL and CMP]. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript. The
corresponding author had full access to all the data in the study and had
final responsibility for the decision to submit for publication.
Parobek et al. GBE
1684 Genome Biol. Evol. 1673–1686 doi:10.1093/gbe/evx126 Advance Access publication July 11, 2017
Acknowledgments
We thank the Cambodian and Thai laboratory and clinical
support staff, and all patients who volunteered for this study.
PPQ, artesunate, and other antimalarials used in the in vitro
drug susceptibility assays were provided by the Chemical
Repository of the Walter Reed Army Institute of Research.
The views expressed in this article are those of the authors
and do not reflect the official policy of the Department of the
Army, Department of Defense, or the U.S. Government. We
would also like to thank Corbin Jones, Praveen Sethupathy,
and Kristina De Paris for their insightful comments.
Literature Cited
Amato R, et al. 2017. Genetic markers associated with dihydroartemisinin-
piperaquine failure in Plasmodium falciparum malaria in Cambodia: a
genotype–phenotype association study. Lancet Infect Dis.
17:164–173.
Ariey F, et al. 2014. A molecular marker of artemisinin-resistant
Plasmodium falciparum malaria. Nature 505:50–55.
Ashley EA, et al. 2014. Spread of artemisinin resistance in Plasmodium
falciparum malaria. N Engl J Med. 371:411–423.
Barnes DA, Foote SJ, Galatis D, Kemp DJ, Cowman AF. 1992. Selection for
high-level chloroquine resistance results in deamplification of the
pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium
falciparum. EMBO J 11:3067–3075.
Beshir KB, et al. 2010. Measuring the efficacy of anti-malarial drugs in vivo:
quantitative PCR measurement of parasite clearance. Malar J. 9:312.
Cerqueira GC, et al. 2017. Longitudinal genomic surveillance of
Plasmodium falciparum malaria parasites reveals complex genomic
architecture of emerging artemisinin resistance. Genome Biol. 18:78.
Chang H-H, et al. 2012. Genomic sequencing of Plasmodium falciparum
malaria parasites from Senegal reveals the demographic history of the
population. Mol Biol Evol. 29:3427–3439.
Chaorattanakawee S, et al. 2015. Ex vivo drug susceptibility testing and
molecular profiling of clinical Plasmodium falciparum isolates from
Cambodia from 2008 to 2013 suggest emerging piperaquine resis-
tance. Antimicrob Agents Chemother. 59:4631–4643.
Chaorattanakawee S, et al. 2016. Ex vivo piperaquine resistance devel-
oped rapidly in Plasmodium falciparum isolates in northern Cambodia
compared to Thailand. Malar J. 15:519.
Conrad MD, et al. 2014. Comparative impacts over 5 years of artemisinin-
based combination therapies on Plasmodium falciparum polymor-
phisms that modulate drug sensitivity in Ugandan children. J Infect
Dis. 210:344–353.
Daniels R, et al. 2013. Genetic surveillance detects both clonal and epi-
demic transmission of malaria following enhanced intervention in
Senegal. PLoS One 8:e60780.
Duru V, et al. 2015. Plasmodium falciparum dihydroartemisinin-
piperaquine failures in Cambodia are associated with mutant K13
parasites presenting high survival rates in novel piperaquine in vitro
assays: retrospective and prospective investigations. BMC Med.
13:305.
Eastman RT, Dharia NV, Winzeler EA, Fidock DA. 2011. Piperaquine resis-
tance is associated with a copy number variation on chromosome 5 in
drug-pressured Plasmodium falciparum parasites. Antimicrob Agents
Chemother. 55:3908–3916.
van Es HH, et al. 1994. Expression of the plasmodial pfmdr1 gene in
mammalian cells is associated with increased susceptibility to chloro-
quine. Mol Cell Biol. 14:2419–2428.
Fairhurst RM. 2015. Understanding artemisinin-resistant malaria: what a
difference a year makes. Curr Opin Infect Dis. 28:417–425.
Ghidelli-Disse S, et al. 2014. Identification of Plasmodium PI4 kinase as
target of MMV390048 by chemoproteomics. Malar J. 13:P38.
Gutenkunst RN, Hernandez RD, Williamson SH, Bustamante CD. 2009.
Inferring the joint demographic history of multiple populations from
multidimensional SNP frequency data. PLoS Genet. 5:e1000695.
Gu Z, Gu L, Eils R, Schlesner M, Brors B. 2014. circlize Implements and
enhances circular visualization in R. Bioinformatics 30:2811–2812.
Hudson RR. 2002. Generating samples under a Wright–Fisher neutral
model of genetic variation. Bioinformatics 18:337–338.
Hurst LD. 2009. Fundamental concepts in genetics: genetics and the un-
derstanding of selection. Nat Rev Genet. 10:83–93.
Imwong M, et al. 2017. The spread of artemisinin-resistant Plasmodium
falciparum in the Greater Mekong subregion: a molecular epidemiol-
ogy observational study. Lancet Infect Dis. 17:491–497.
Jombart T, Ahmed I. 2011. adegenet 1.3-1: new tools for the analysis of
genome-wide SNP data. Bioinformatics 27:3070–3071.
Kreitman M. 2000. Methods to detect selection in populations with appli-
cations to the human. Annu Rev Genomics Hum Genet. 1:539–559.
Leang R, et al. 2015. Evidence of Plasmodium falciparum malaria multi-
drug resistance to artemisinin and piperaquine in Western Cambodia:
dihydroartemisinin-piperaquine open-label multicenter clinical assess-
ment. Antimicrob Agents Chemother. 59:4719–4726.
Lim P, et al. 2015. Decreasing pfmdr1 copy number suggests that
Plasmodium falciparum in Western Cambodia is regaining in vitro sus-
ceptibility to mefloquine. Antimicrob Agents Chemother.
59:2934–2937.
MalariaGEN Plasmodium falciparum Community Project. 2016. Genomic
epidemiology of artemisinin resistant malaria. Elife 5. doi: 10.7554/
eLife.08714.
Maruyama T, Fuerst PA. 1984. Population bottlenecks and nonequilibrium
models in population genetics. I. Allele numbers when populations
evolve from zero variability. Genetics 108:745–763.
Maxmen A. 2016. Back on TRAC: new trial launched in bid to outpace
multidrug-resistant malaria. Nat Med. 22:220–221.
McCoy RC, Garud NR, Kelley JL, Boggs CL, Petrov DA. 2014. Genomic
inference accurately predicts the timing and severity of a recent bot-
tleneck in a nonmodel insect population. Mol Ecol. 23:136–150.
McNamara CW, et al. 2013. Targeting Plasmodium PI(4)K to eliminate
malaria. Nature 504:248–253.
Miotto O, et al. 2015. Genetic architecture of artemisinin-resistant
Plasmodium falciparum. Nat Genet. 47:226–234.
Miotto O, et al. 2013. Multiple populations of artemisinin-resistant
Plasmodium falciparum in Cambodia. Nat Genet. 45:648–655.
Mukherjee A, et al. 2017. Artemisinin resistance without pfkelch13 muta-
tions in Plasmodium falciparum isolates from Cambodia. Malar J.
16:195.
Nair S, et al. 2007. Recurrent gene amplification and soft selective sweeps
during evolution of multidrug resistance in malaria parasites. Mol Biol
Evol. 24:562–573.
Nielsen R, Rasmus N. 2005. Molecular signatures of natural selection.
Annu Rev Genet. 39:197–218.
Paradis E. 2010. pegas: an R package for population genetics with an
integrated-modular approach. Bioinformatics 26:419–420.
Paradis E, Claude J, Strimmer K. 2004. APE: analyses of phylogenetics and
evolution in R language. Bioinformatics 20:289–290.
Parobek CM, et al. 2016. Selective sweep suggests transcriptional regula-
tion may underlie Plasmodium vivax resilience to malaria control meas-
ures in Cambodia. Proc Natl Acad Sci U S A. 113:E8096–E8105.
Pfeifer B, Wittelsbu¨rger U, Ramos-Onsins SE, Lercher MJ. 2014.
PopGenome: an efficient Swiss army knife for population genomic
analyses in R. Mol Biol Evol. 31:1929–1936.
Genetic Architecture of ACT Partner Drug Resistance GBE
Genome Biol. Evol. 1673–1686 doi:10.1093/gbe/evx126 Advance Access publication July 11, 2017 1685
Robinson JD, Coffman AJ, Hickerson MJ, Gutenkunst RN. 2014. Sampling
strategies for frequency spectrum-based population genomic infer-
ence. BMC Evol Biol. 14:254.
Rutvisuttinunt W, et al. 2012. Optimizing the HRP-2 in vitro malaria drug
susceptibility assay using a reference clone to improve comparisons of
Plasmodium falciparum field isolates. Malar J. 11:325.
Saunders DL, et al. 2015. Atovaquone-proguanil remains a potential stop-
gap therapy for multidrug-resistant Plasmodium falciparum in areas
along the Thai-Cambodian border. Antimicrob Agents Chemother.
60:1896–1898.
Saunders D, Lon C. 2016. Combination therapies for malaria are failing:
what next?. Lancet Infect Dis. 16:274–275.
Shanks GD, Edstein MD, Jacobus D. 2015. Evolution from double to triple-
antimalarial drug combinations. Trans R Soc Trop Med Hyg.
109:182–188.
Spring MD, et al. 2015. Dihydroartemisinin-piperaquine failure associated
with a triple mutant including kelch13 C580Y in Cambodia: an ob-
servational cohort study. Lancet Infect Dis. 15:683–691.
Takala-Harrison S, et al. 2012. Genetic loci associated with delayed clear-
ance of Plasmodium falciparum following artemisinin treatment in
Southeast Asia. Proc Natl Acad Sci U S A. 110:240–245.
Taylor SM, Juliano JJ. 2014. Artemisinin combination therapies and
malaria parasite drug resistance: the game is afoot. J Infect Dis.
210:335–337.
Veiga MI, et al. 2014. Complex polymorphisms in the plasmodium
falciparum multidrug resistance protein 2 gene and its contribution
to antimalarial response. Antimicrob Agents Chemother.
58:7390–7397.
Venkatesan M, et al. 2014. Polymorphisms in Plasmodium falciparum chlo-
roquine resistance transporter and multidrug resistance 1 genes: par-
asite risk factors that affect treatment outcomes for P. falciparum
malaria after artemether-lumefantrine and artesunate-amodiaquine.
Am J Trop Med Hyg. 91:833–843.
Wang Z, et al. 2016. Genome-wide association analysis identifies genetic
loci associated with resistance to multiple antimalarials in Plasmodium
falciparum from China-Myanmar border. Sci Rep. 6:33891.
Witkowski B, et al. 2017. A surrogate marker of piperaquine-resistant
Plasmodium falciparum malaria: a phenotype-genotype association
study. Lancet Infect Dis. 17:174–183.
Associate editor: Geoff McFadden
Parobek et al. GBE
1686 Genome Biol. Evol. 1673–1686 doi:10.1093/gbe/evx126 Advance Access publication July 11, 2017
